ArticleNeuropsychiatric disease and treatment2005
Combination/augmentation strategies for improving the treatment of depression.
Article in Neuropsychiatric disease and treatment, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effects of different physical activity interventions on depressive symptoms in menopausal women: a systematic review and network meta-analysis.BMC public health · 2025Pooled it
- Ascending single-dose study of the safety, pharmacokinetics, and pharmacodynamics of CSTI-500, a novel monoamine triple reuptake inhibitor, first-in-human.Psychopharmacology · 2026Trial
- A Preliminary Study of Different Treatment Strategies for Anxious Depression.Neuropsychiatric disease and treatment · 2022Trial
- Mental Health Disorders in End-Stage Kidney Disease: A Narrative Review of Clinical Considerations for Integrated Management.Hemodialysis international. International Symposium on Home Hemodialysis · 2026Review
- Lamotrigine and Fluoxetine Overdose Presenting With Severe Neuro-Cardiotoxicity: A Case Report.Cureus · 2026Article
- Exploring New Frontiers in Pharmacological Treatment of Depression: A Review on Recent Advances.Current medicinal chemistry · 2026Review
- Chronic, combinatorial targeting of NMDARs and 5-HTNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Article
- Investigation of Pharmacokinetic and Pharmacodynamic Interactions between Citalopram and Duloxetine: An Integrated Analytical, Computational, Behavioral, and Biochemical Approach.ACS pharmacology & translational science · 2024Article
- Polygenic risk scores of lithium response and treatment resistance in major depressive disorder.Translational psychiatry · 2023Article
- Investigating genetic overlap between antidepressant and lithium response and treatment resistance in major depressive disorder.Research square · 2023Article
- The Use of Psychotropic Medication in Pediatric Oncology for Acute Psychological and Psychiatric Problems: Balancing Risks and Benefits.Children (Basel, Switzerland) · 2022Review
- Gender Differences in Demographic and Pharmacological Factors in Patients Diagnosed with Late-Onset of Alzheimer's Disease.Brain sciences · 2022Article
- Low doses of ketamine and guanosine abrogate corticosterone-induced anxiety-related behavior, but not disturbances in the hippocampal NLRP3 inflammasome pathway.Psychopharmacology · 2021Article
- Translational application of neuroimaging in major depressive disorder: a review of psychoradiological studies.Frontiers of medicine · 2021Review
- Fabrication and Characterization of Fast-Dissolving Films Containing Escitalopram/Quetiapine for the Treatment of Major Depressive Disorder.Pharmaceutics · 2021Article
- A Preliminary Randomized Controlled Trial of Different Treatment Regimens for Melancholic Depression.Neuropsychiatric disease and treatment · 2021Article
- Encapsulated Escitalopram and Paroxetine Intranasal Co-Administration:Frontiers in pharmacology · 2021Article
- Ketamine: The final frontier or another depressing end?Behavioural brain research · 2020Review
- Neuroprotective Potency of Saffron Against Neuropsychiatric Diseases, Neurodegenerative Diseases, and Other Brain Disorders: From Bench to Bedside.Frontiers in pharmacology · 2020Review
- Neuronal life or death linked to depression treatment: the interplay between drugs and their stress-related outcomes relate to single or combined drug therapies.Apoptosis : an international journal on programmed cell death · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Depression is a common and debilitating condition, with considerable impact for depressed individuals and a heavy burden for society. In spite of its prevalence, depression is underrecognized and under- or inappropriately treated. In spite of the large number of antidepressants available at the present time, they are far from ideal and all show a similar slow, and frequently, incomplete response. Thus, the need for new and better compounds is as urgent and compelling as ever. While waiting for the panacea of future antidepressants, clinicians have developed a variety of associations of several antidepressants or an antidepressant with a second different agent. This article reviews the various strategies adopted by clinicians in the hope of increasing the response rate of current antidepressants to obtain full remission and/or to overcome treatment-resistant depression.
Indexed as
Identifiers
18568111PMC2424118What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.